Connection
Janet Rader to Aged
This is a "connection" page, showing publications Janet Rader has written about Aged.
|
|
Connection Strength |
|
|
|
|
|
0.700 |
|
|
|
-
Zighelboim I, Wright JD, Gao F, Case AS, Massad LS, Mutch DG, Powell MA, Thaker PH, Eisenhauer EL, Cohn DE, Valea FA, Alvarez Secord A, Lippmann LT, Dehdashti F, Rader JS. Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. Gynecol Oncol. 2013 Jul; 130(1):64-8.
Score: 0.043
-
Nugent EK, Case AS, Hoff JT, Zighelboim I, DeWitt LL, Trinkhaus K, Mutch DG, Thaker PH, Massad LS, Rader JS. Chemoradiation in locally advanced cervical carcinoma: an analysis of cisplatin dosing and other clinical prognostic factors. Gynecol Oncol. 2010 Mar; 116(3):438-41.
Score: 0.034
-
Kizer N, Zighelboim I, Rader JS. Cardiac arrest during laparotomy with argon beam coagulation of metastatic ovarian cancer. Int J Gynecol Cancer. 2009 Feb; 19(2):237-8.
Score: 0.032
-
Rader JS, Aylsworth CF, Juckett DA, Mutch DG, Powell MA, Lippmann L, Dimitrov NV. Phase I study and preliminary pharmacology of the novel innate immune modulator rBBX-01 in gynecologic cancers. Clin Cancer Res. 2008 May 15; 14(10):3089-97.
Score: 0.030
-
Wright JD, Gibb RK, Geevarghese S, Powell MA, Herzog TJ, Mutch DG, Grigsby PW, Gao F, Trinkaus KM, Rader JS. Cervical carcinoma in the elderly: an analysis of patterns of care and outcome. Cancer. 2005 Jan 01; 103(1):85-91.
Score: 0.024
-
Summey RM, Gornstein E, Decker B, Dougherty KC, Rader JS, Hopp E. Landscape of potential germline pathogenic variants in select cancer susceptibility genes in patients with adult-type ovarian granulosa cell tumors. Cancer Med. 2024 Jun; 13(12):e7340.
Score: 0.023
-
Moh M, Puzyrenko A, Summey R, Rader JS, Herrera Cano GE, Gavina JV, Rui H, Sun Y, Hopp E. Clinicopathologic Characteristics of a Single-institution Cohort of Ovarian Adult Granulosa Cell Tumors, With Biomarker and Therapeutic Implications Utilizing the Detection of Androgen, Estrogen, and Progesterone Hormone Receptor Expression by Immunohistochemistry. Int J Gynecol Pathol. 2024 Sep 01; 43(5):527-534.
Score: 0.023
-
Rader JS, Clarke-Pearson D, Moore M, Carson L, Holloway R, Kao MS, Wiznitzer I, Douglass EC. A phase II study to determine the efficacy and tolerability of intravenous ZD9331 in heavily pretreated patients with ovarian cancer. Gynecol Oncol. 2003 Nov; 91(2):318-25.
Score: 0.022
-
Grigsby PW, Perez CA, Chao KS, Herzog T, Mutch DG, Rader J. Radiation therapy for carcinoma of the cervix with biopsy-proven positive para-aortic lymph nodes. Int J Radiat Oncol Biol Phys. 2001 Mar 01; 49(3):733-8.
Score: 0.018
-
Swisher EM, Babb S, Whelan A, Mutch DG, Rader JS. Prophylactic oophorectomy and ovarian cancer surveillance. Patient perceptions and satisfaction. J Reprod Med. 2001 Feb; 46(2):87-94.
Score: 0.018
-
Gagliardi A, Porter VL, Zong Z, Bowlby R, Titmuss E, Namirembe C, Griner NB, Petrello H, Bowen J, Chan SK, Culibrk L, Darragh TM, Stoler MH, Wright TC, Gesuwan P, Dyer MA, Ma Y, Mungall KL, Jones SJM, Nakisige C, Novik K, Orem J, Origa M, Gastier-Foster JM, Yarchoan R, Casper C, Mills GB, Rader JS, Ojesina AI, Gerhard DS, Mungall AJ, Marra MA. Analysis of Ugandan cervical carcinomas identifies human papillomavirus clade-specific epigenome and transcriptome landscapes. Nat Genet. 2020 08; 52(8):800-810.
Score: 0.018
-
Brooks RA, Tritchler DS, Darcy KM, Lankes HA, Salani R, Sperduto P, Guntupalli S, DiSilvestro P, Kesterson J, Olawaiye AB, Moxley K, Waggoner S, Santin A, Rader JS, Kizer NT, Thaker PH, Powell MA, Mutch DG, Birrer MJ, Goodfellow PJ. GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2019 05; 153(2):335-342.
Score: 0.016
-
Harold JA, Uyar D, Rader JS, Bishop E, Nugent M, Simpson P, Bradley WH. Adipose-only sentinel lymph nodes: a finding during the adaptation of a sentinel lymph node mapping algorithm with indocyanine green in women with endometrial cancer. Int J Gynecol Cancer. 2019 01; 29(1):53-59.
Score: 0.016
-
Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Sivakumar IKA, Gentles AJ, Malhotra R, Farshidfar F, Colaprico A, Parker JS, Mose LE, Vo NS, Liu J, Liu Y, Rader J, Dhankani V, Reynolds SM, Bowlby R, Califano A, Cherniack AD, Anastassiou D, Bedognetti D, Mokrab Y, Newman AM, Rao A, Chen K, Krasnitz A, Hu H, Malta TM, Noushmehr H, Pedamallu CS, Bullman S, Ojesina AI, Lamb A, Zhou W, Shen H, Choueiri TK, Weinstein JN, Guinney J, Saltz J, Holt RA, Rabkin CS, Lazar AJ, Serody JS, Demicco EG, Disis ML, Vincent BG, Shmulevich I. The Immune Landscape of Cancer. Immunity. 2018 04 17; 48(4):812-830.e14.
Score: 0.015
-
Liapis H, Adler LM, Wick MR, Rader JS. Expression of alpha(v)beta3 integrin is less frequent in ovarian epithelial tumors of low malignant potential in contrast to ovarian carcinomas. Hum Pathol. 1997 Apr; 28(4):443-9.
Score: 0.014
-
Divine LM, Kizer NT, Hagemann AR, Pittman ME, Chen L, Powell MA, Mutch DG, Rader JS, Thaker PH. Clinicopathologic characteristics and survival of patients with gynecologic malignancies metastatic to the brain. Gynecol Oncol. 2016 07; 142(1):76-82.
Score: 0.013
-
Kharofa J, Morrow N, Kelly T, Rownd J, Paulson E, Rader J, Uyar D, Bradley W, Erickson B. 3-T MRI-based adaptive brachytherapy for cervix cancer: treatment technique and initial clinical outcomes. Brachytherapy. 2014 Jul-Aug; 13(4):319-25.
Score: 0.012
-
Liapis H, Crouch EC, Roby J, Rader JS. In situ localization of parathyroid hormone-like protein and mRNA in intraepithelial neoplasia and invasive carcinoma of the uterine cervix. Hum Pathol. 1993 Oct; 24(10):1058-66.
Score: 0.011
-
Schwarz JK, Payton JE, Rashmi R, Xiang T, Jia Y, Huettner P, Rogers BE, Yang Q, Watson M, Rader JS, Grigsby PW. Pathway-specific analysis of gene expression data identifies the PI3K/Akt pathway as a novel therapeutic target in cervical cancer. Clin Cancer Res. 2012 Mar 01; 18(5):1464-71.
Score: 0.010
-
Kizer NT, Thaker PH, Gao F, Zighelboim I, Powell MA, Rader JS, Mutch DG, Grigsby PW. The effects of body mass index on complications and survival outcomes in patients with cervical carcinoma undergoing curative chemoradiation therapy. Cancer. 2011 Mar 01; 117(5):948-56.
Score: 0.009
-
Fracasso PM, Williams KJ, Chen RC, Picus J, Ma CX, Ellis MJ, Tan BR, Pluard TJ, Adkins DR, Naughton MJ, Rader JS, Arquette MA, Fleshman JW, Creekmore AN, Goodner SA, Wright LP, Guo Z, Ryan CE, Tao Y, Soares EM, Cai SR, Lin L, Dancey J, Rudek MA, McLeod HL, Piwnica-Worms H. A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies. Cancer Chemother Pharmacol. 2011 Jun; 67(6):1225-37.
Score: 0.009
-
Showalter TN, Miller TR, Huettner P, Rader J, Grigsby PW. 18F-fluorodeoxyglucose-positron emission tomography and pathologic tumor size in early-stage invasive cervical cancer. Int J Gynecol Cancer. 2009 Nov; 19(8):1412-4.
Score: 0.008
-
Kidd EA, Spencer CR, Huettner PC, Siegel BA, Dehdashti F, Rader JS, Grigsby PW. Cervical cancer histology and tumor differentiation affect 18F-fluorodeoxyglucose uptake. Cancer. 2009 Aug 01; 115(15):3548-54.
Score: 0.008
-
Nugent EK, Zighelboim I, Case AS, Gao F, Thaker PH, Rader JS, Mutch DG, Massad LS. The value of perioperative imaging in patients with uterine sarcomas. Gynecol Oncol. 2009 Oct; 115(1):37-40.
Score: 0.008
-
Brooks RA, Rader JS, Dehdashti F, Mutch DG, Powell MA, Thaker PH, Siegel BA, Grigsby PW. Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer. Gynecol Oncol. 2009 Jan; 112(1):104-9.
Score: 0.008
-
Herzog TJ, Powell MA, Rader JS, Gibb RK, Lippmann L, Coleman RL, Mutch DG. Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer. Gynecol Oncol. 2008 Dec; 111(3):467-73.
Score: 0.008
-
Nguyen TT, Wright JD, Powell MA, Gibb RK, Rader JS, Allsworth JE, Mutch DG. Prognostic factors associated with response in platinum retreatment of platinum-resistant ovarian cancer. Int J Gynecol Cancer. 2008 Nov-Dec; 18(6):1194-9.
Score: 0.007
-
Tierney RM, Powell MA, Mutch DG, Gibb RK, Rader JS, Grigsby PW. Acute toxicity of postoperative IMRT and chemotherapy for endometrial cancer. Radiat Med. 2007 Nov; 25(9):439-45.
Score: 0.007
-
Wright JD, Grigsby PW, Brooks R, Powell MA, Gibb RK, Gao F, Rader JS, Mutch DG. Utility of parametrectomy for early stage cervical cancer treated with radical hysterectomy. Cancer. 2007 Sep 15; 110(6):1281-6.
Score: 0.007
-
Wright JD, Powell MA, Rader JS, Mutch DG, Gibb RK. Bevacizumab therapy in patients with recurrent uterine neoplasms. Anticancer Res. 2007 Sep-Oct; 27(5B):3525-8.
Score: 0.007
-
Wright JD, Grigsby PW, Rader JS, Mutch DG, Powell MA, Gao F, Gibb RK. Effect of a T0 radical hysterectomy specimen on survival for early stage cervical cancer. Gynecol Oncol. 2007 Nov; 107(2):280-4.
Score: 0.007
-
Wright JD, Secord AA, Numnum TM, Rocconi RP, Powell MA, Berchuck A, Alvarez RD, Gibb RK, Trinkaus K, Rader JS, Mutch DG. A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer. Int J Gynecol Cancer. 2008 May-Jun; 18(3):400-6.
Score: 0.007
-
Lin LL, Mutch DG, Rader JS, Powell MA, Grigsby PW. External radiotherapy versus vaginal brachytherapy for patients with intermediate risk endometrial cancer. Gynecol Oncol. 2007 Jul; 106(1):215-20.
Score: 0.007
-
Fayed A, Mutch DG, Rader JS, Gibb RK, Powell MA, Wright JD, Elnaqa I, Zoberi I, Grigsby PW. Comparison of high-dose-rate and low-dose-rate brachytherapy in the treatment of endometrial carcinoma. Int J Radiat Oncol Biol Phys. 2007 Feb 01; 67(2):480-4.
Score: 0.007
-
McCourt CK, Mutch DG, Gibb RK, Rader JS, Goodfellow PJ, Trinkaus K, Powell MA. Body mass index: relationship to clinical, pathologic and features of microsatellite instability in endometrial cancer. Gynecol Oncol. 2007 Mar; 104(3):535-9.
Score: 0.007
-
Wright JD, Hagemann A, Rader JS, Viviano D, Gibb RK, Norris L, Mutch DG, Powell MA. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis. Cancer. 2006 Jul 01; 107(1):83-9.
Score: 0.007
-
Taylor NP, Zighelboim I, Huettner PC, Powell MA, Gibb RK, Rader JS, Mutch DG, Edmonston TB, Goodfellow PJ. DNA mismatch repair and TP53 defects are early events in uterine carcinosarcoma tumorigenesis. Mod Pathol. 2006 Oct; 19(10):1333-8.
Score: 0.007
-
Herzog TJ, Powell MA, Rader JS, Gibb R, Mutch DG. Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer. Gynecol Oncol. 2006 Nov; 103(2):637-41.
Score: 0.007
-
Gossner G, Coleman RL, Mutch DG, Horowitz NS, Rader JS, Gibb RK, Powell MA, Herzog TJ. CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan. Gynecol Oncol. 2006 Oct; 103(1):212-8.
Score: 0.007
-
Wright JD, Rosenbush EJ, Powell MA, Rader JS, Mutch DG, Gao F, Gibb RK. Long-term outcome of women who undergo panniculectomy at the time of gynecologic surgery. Gynecol Oncol. 2006 Jul; 102(1):86-91.
Score: 0.006
-
Lewin SN, Buttin BM, Powell MA, Gibb RK, Rader JS, Mutch DG, Herzog TJ. Resource utilization for ovarian cancer patients at the end of life: how much is too much? Gynecol Oncol. 2005 Nov; 99(2):261-6.
Score: 0.006
-
Wright JD, Powell MA, Mutch DG, Rader JS, Gibb RK, Gao F, Herzog TJ. Relationship of ovarian neoplasms and body mass index. J Reprod Med. 2005 Aug; 50(8):595-602.
Score: 0.006
-
Wright JD, Rosenblum K, Huettner PC, Mutch DG, Rader JS, Powell MA, Gibb RK. Cervical sarcomas: an analysis of incidence and outcome. Gynecol Oncol. 2005 Nov; 99(2):348-51.
Score: 0.006
-
Fracasso PM, Goldstein LJ, de Alwis DP, Rader JS, Arquette MA, Goodner SA, Wright LP, Fears CL, Gazak RJ, Andre VA, Burgess MF, Slapak CA, Schellens JH. Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies. Clin Cancer Res. 2004 Nov 01; 10(21):7220-8.
Score: 0.006
-
Rutledge TL, Kamelle SA, Tillmanns TD, Gould NS, Wright JD, Cohn DE, Herzog TJ, Rader JS, Gold MA, Johnson GA, Walker JL, Mannel RS, McMeekin DS. A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference? Gynecol Oncol. 2004 Oct; 95(1):70-6.
Score: 0.006
-
Kamelle SA, Rutledge TL, Tillmanns TD, Gould NS, Cohn DE, Wright J, Herzog TJ, Rader JS, Gold MA, Johnson GA, Walker JL, Mannel RS, McMeekin DS. Surgical-pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply? Gynecol Oncol. 2004 Aug; 94(2):249-55.
Score: 0.006
-
Grigsby PW, Singh AK, Siegel BA, Dehdashti F, Rader J, Zoberi I. Lymph node control in cervical cancer. Int J Radiat Oncol Biol Phys. 2004 Jul 01; 59(3):706-12.
Score: 0.006
-
Buttin BM, Powell MA, Mutch DG, Babb SA, Huettner PC, Edmonston TB, Herzog TJ, Rader JS, Gibb RK, Whelan AJ, Goodfellow PJ. Penetrance and expressivity of MSH6 germline mutations in seven kindreds not ascertained by family history. Am J Hum Genet. 2004 Jun; 74(6):1262-9.
Score: 0.006
-
Wright JD, Powell MA, Mutch DG, Rader JS, Gibb RK, Huettner PC, Herzog TJ. Synchronous ovarian metastases at the time of laparotomy for colon cancer. Gynecol Oncol. 2004 Mar; 92(3):851-5.
Score: 0.006
-
Buttin BM, Powell MA, Mutch DG, Rader JS, Herzog TJ, Gibb RK, Huettner P, Edmonston TB, Goodfellow PJ. Increased risk for hereditary nonpolyposis colorectal cancer-associated synchronous and metachronous malignancies in patients with microsatellite instability-positive endometrial carcinoma lacking MLH1 promoter methylation. Clin Cancer Res. 2004 Jan 15; 10(2):481-90.
Score: 0.006
-
Armstrong DK, Blessing JA, Rader J, Sorosky JI. A randomized phase II evaluation of bryostatin-1 (NSC #339555) in persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study. Invest New Drugs. 2003 Nov; 21(4):453-7.
Score: 0.006
-
Fracasso PM, Rodriguez LC, Herzog TJ, Fears CL, Goodner SA, Govindan R, Picus J, Rader JS, Tan BR, Arquette MA. Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies. Cancer. 2003 Aug 01; 98(3):610-7.
Score: 0.005
-
Fracasso PM, Rader JS, Govindan R, Herzog TJ, Arquette MA, Denes A, Mutch DG, Picus J, Tan BR, Fears CL, Goodner SA, Sun SL. Phase I study of rubitecan and gemcitabine in patients with advanced malignancies. Ann Oncol. 2002 Nov; 13(11):1819-25.
Score: 0.005
-
Horowitz NS, Cohn DE, Herzog TJ, Mutch DG, Rader JS, Bhalla S, Gibb RK. The significance of pneumatosis intestinalis or bowel perforation in patients with gynecologic malignancies. Gynecol Oncol. 2002 Jul; 86(1):79-84.
Score: 0.005
-
Whelan AJ, Babb S, Mutch DG, Rader J, Herzog TJ, Todd C, Ivanovich JL, Goodfellow PJ. MSI in endometrial carcinoma: absence of MLH1 promoter methylation is associated with increased familial risk for cancers. Int J Cancer. 2002 Jun 10; 99(5):697-704.
Score: 0.005
-
Ivanovich J, Babb S, Goodfellow P, Mutch D, Herzog T, Rader J, Whelan A. Evaluation of the family history collection process and the accuracy of cancer reporting among a series of women with endometrial cancer. Clin Cancer Res. 2002 Jun; 8(6):1849-56.
Score: 0.005
-
Powell MA, Mutch DG, Rader JS, Herzog TJ, Huang TH, Goodfellow PJ. Ribosomal DNA methylation in patients with endometrial carcinoma: an independent prognostic marker. Cancer. 2002 Jun 01; 94(11):2941-52.
Score: 0.005
-
Bloss JD, Blessing JA, Behrens BC, Mannel RS, Rader JS, Sood AK, Markman M, Benda J. Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2002 Apr 01; 20(7):1832-7.
Score: 0.005
-
Cohn DE, Dehdashti F, Gibb RK, Mutch DG, Rader JS, Siegel BA, Herzog TJ. Prospective evaluation of positron emission tomography for the detection of groin node metastases from vulvar cancer. Gynecol Oncol. 2002 Apr; 85(1):179-84.
Score: 0.005
-
Swisher EM, Cohn DE, Goff BA, Parham J, Herzog TJ, Rader JS, Mutch DG. Use of complementary and alternative medicine among women with gynecologic cancers. Gynecol Oncol. 2002 Mar; 84(3):363-7.
Score: 0.005
-
Plaxe SC, Blessing JA, Husseinzadeh N, Webster KD, Rader JS, Dunton CJ. Phase II trial of pyrazoloacridine in patients with persistent or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2002 Feb; 84(2):241-4.
Score: 0.005
-
Buttin BM, Herzog TJ, Powell MA, Rader JS, Mutch DG. Epithelial ovarian tumors of low malignant potential: the role of microinvasion. Obstet Gynecol. 2002 Jan; 99(1):11-7.
Score: 0.005
-
Cohn DE, Mutch DG, Rader JS, Farrell M, Awantang R, Herzog TJ. Factors predicting subcutaneous implanted central venous port function: the relationship between catheter tip location and port failure in patients with gynecologic malignancies. Gynecol Oncol. 2001 Dec; 83(3):533-6.
Score: 0.005
-
O'sullivan MJ, Rader JS, Gerhard DS, Li Y, Trinkaus KM, Gersell DJ, Huettner PC. Loss of heterozygosity at 11q23.3 in vasculoinvasive and metastatic squamous cell carcinoma of the cervix. Hum Pathol. 2001 May; 32(5):475-8.
Score: 0.005
-
Cohn DE, Swisher EM, Herzog TJ, Rader JS, Mutch DG. Radical hysterectomy for cervical cancer in obese women. Obstet Gynecol. 2000 Nov; 96(5 Pt 1):727-31.
Score: 0.005
-
Cohn DE, Babb S, Whelan AJ, Mutch DG, Herzog TJ, Rader JS, Elbendary A, Goodfellow PJ. Atypical clustering of gynecologic malignancies: A family study including molecular analysis of candidate genes. Gynecol Oncol. 2000 Apr; 77(1):18-25.
Score: 0.004
-
Grigsby PW, Perez CA, Chao KS, Elbendary A, Herzog TJ, Rader JS, Mutch DG. Lack of effect of tumor size on the prognosis of carcinoma of the uterine cervix Stage IB and IIA treated with preoperative irradiation and surgery. Int J Radiat Oncol Biol Phys. 1999 Oct 01; 45(3):645-51.
Score: 0.004
-
Swisher EM, Mutch DG, Rader JS, Elbendary A, Herzog TJ. Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecol Oncol. 1997 Sep; 66(3):480-6.
Score: 0.004
-
Kowalski LD, Mutch DG, Herzog TJ, Rader JS, Goodfellow PJ. Mutational analysis of MLH1 and MSH2 in 25 prospectively-acquired RER+ endometrial cancers. Genes Chromosomes Cancer. 1997 Mar; 18(3):219-27.
Score: 0.003
-
Leake JF, Rader JS, Woodruff JD, Rosenshein NB. Retroperitoneal lymphatic involvement with epithelial ovarian tumors of low malignant potential. Gynecol Oncol. 1991 Aug; 42(2):124-30.
Score: 0.002
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|